Log in to your Inderes Free account to see all free content on this page.
PILA PHARMA
1.70 SEK
+0.89 %
Less than 1K followers
PILA
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
+0.89 %
+3.99 %
+41.25 %
-17.72 %
-22.25 %
-35.48 %
-37.29 %
-
-78.30 %
PILA PHARMA is a clinical stage biotechnology company based in Malmö, Sweden. The company is developing novel oral therapeutics for globally common metabolic diseases such as Diabetes, Obesity and Cardiovascular diseases as well as therapeutics for Pain treatment. The company has obtained an orphan drug designation in the United States for the rare disease Erythromelalgia. The company is specializing in development of pharmaceutical drugs based on TRPV1-antagonists.
Read moreMarket cap
77.43M SEK
Turnover
8.08K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
27.8.
2026
Interim report Q2'26
25.2.
2027
Annual report '26
All
Webcasts
Press releases
ShowingAll content types
PILA PHARMA: UPCOMING INVESTOR EVENTS AND INTERVIEWS - PRESENTING AT REDEYE DIABETES DAY ON 06 MAY
BioStock: Pila Pharma on the preclinical results and the way forward
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio